Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Aclaris Therapeutics (NASDAQ:ACRS) and maintained a $38 price target.
September 19, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Aclaris Therapeutics and maintained a $38 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Aclaris Therapeutics. The maintained price target of $38 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100